BIENAIME JEAN JACQUES 4

What Happened

• Jean-Jacques Bienaime, a director of Immunome (IMNM), completed offsetting open-market sales and purchases on June 5, 2026.
• Sales: 10,500 shares sold in two trades — 500 @ $19.44 ($9,720) and 10,000 @ $19.41 ($194,100) — total proceeds $203,820.
• Purchases: 10,500 shares acquired in three trades — 6,000 @ $19.48 ($116,880), 3,500 @ $19.46 ($68,110), and 1,000 @ $19.27 ($19,270) — total cost $204,260.
• Net effect: same number of shares sold and repurchased (10,500); purchases slightly exceeded sales by $440. These were open-market trades (P = purchase, S = sale).

Key Details

• Transaction date: June 5, 2026 (Form 4 filed June 9, 2026 — appears timely under the 2-business-day rule).
• Prices and amounts:
  • Sales: 500 @ $19.44 ($9,720); 10,000 @ $19.41 ($194,100).
  • Purchases: 6,000 @ $19.48 ($116,880); 3,500 @ $19.46 ($68,110); 1,000 @ $19.27 ($19,270).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Footnotes:
  • F1: The sale was matchable under Section 16(b); Bienaime agreed to pay the issuer $155 upon settlement representing the short‑swing profit.
  • F2: Confirms the reporting person sold and reacquired the same aggregate number of shares on June 5, 2026.
• Filing timeliness: filed June 9 for June 5 transactions — filing appears timely (not marked late).

Context

• These were routine open-market trades that offset one another on the same day. Because the sale and repurchase were matchable under Section 16(b), the reporting person agreed to remit the small short‑swing profit ($155) to the company — a technical compliance outcome rather than a clear buy/sell signal.
• For retail investors: purchases can be more informative than sales, but here the net position didn’t change (same shares sold and bought), so this filing does not reveal a change in insider ownership or an obvious directional bet.